196 related articles for article (PubMed ID: 35628777)
21. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases.
Kaźmierczak-Siedlecka K; Ruszkowski J; Fic M; Folwarski M; Makarewicz W
Curr Microbiol; 2020 Sep; 77(9):1987-1996. PubMed ID: 32472262
[TBL] [Abstract][Full Text] [Related]
22. Generation of a Uracil Auxotroph Strain of the Probiotic Yeast Saccharomyces boulardii as a Host for the Recombinant Protein Production.
Hamedi H; Misaghi A; Modarressi MH; Salehi TZ; Khorasanizadeh D; Khalaj V
Avicenna J Med Biotechnol; 2013 Jan; 5(1):29-34. PubMed ID: 23626874
[TBL] [Abstract][Full Text] [Related]
23. Genetic basis for probiotic yeast phenotypes revealed by nanopore sequencing.
Collins JH; Kunyeit L; Weintraub S; Sharma N; White C; Haq N; Anu-Appaiah KA; Rao RP; Young EM
G3 (Bethesda); 2023 Aug; 13(8):. PubMed ID: 37103477
[TBL] [Abstract][Full Text] [Related]
24. Seven cases of Saccharomyces fungaemia related to use of probiotics.
Roy U; Jessani LG; Rudramurthy SM; Gopalakrishnan R; Dutta S; Chakravarty C; Jillwin J; Chakrabarti A
Mycoses; 2017 Jun; 60(6):375-380. PubMed ID: 28133894
[TBL] [Abstract][Full Text] [Related]
25. Candida albicans heme oxygenase and its product CO contribute to pathogenesis of candidemia and alter systemic chemokine and cytokine expression.
Navarathna DH; Roberts DD
Free Radic Biol Med; 2010 Nov; 49(10):1561-73. PubMed ID: 20800092
[TBL] [Abstract][Full Text] [Related]
26. Fungal heme oxygenases: Functional expression and characterization of Hmx1 from Saccharomyces cerevisiae and CaHmx1 from Candida albicans.
Kim D; Yukl ET; Moënne-Loccoz P; Montellano PR
Biochemistry; 2006 Dec; 45(49):14772-80. PubMed ID: 17144670
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the Probiotic Yeast Saccharomyces boulardii in the Healthy Mucosal Immune System.
Hudson LE; McDermott CD; Stewart TP; Hudson WH; Rios D; Fasken MB; Corbett AH; Lamb TJ
PLoS One; 2016; 11(4):e0153351. PubMed ID: 27064405
[TBL] [Abstract][Full Text] [Related]
28. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
Everard A; Matamoros S; Geurts L; Delzenne NM; Cani PD
mBio; 2014 Jun; 5(3):e01011-14. PubMed ID: 24917595
[TBL] [Abstract][Full Text] [Related]
29. Saccharomyces boulardii and Candida albicans experimental colonization of the murine gut.
Samonis G; Falagas ME; Lionakis S; Ntaoukakis M; Kofteridis DP; Ntalas I; Maraki S
Med Mycol; 2011 May; 49(4):395-9. PubMed ID: 21077734
[TBL] [Abstract][Full Text] [Related]
30.
Lenka S; Singh D; Paul S; Gayen A; Chandra M
ACS Infect Dis; 2021 Apr; 7(4):733-745. PubMed ID: 33703881
[TBL] [Abstract][Full Text] [Related]
31. Quality control of fifteen probiotic products containing Saccharomyces boulardii.
Vanhee LM; Goemé F; Nelis HJ; Coenye T
J Appl Microbiol; 2010 Nov; 109(5):1745-52. PubMed ID: 20636342
[TBL] [Abstract][Full Text] [Related]
32. Identification and Growth Characterization of a Novel Strain of
Hossain MN; Afrin S; Humayun S; Ahmed MM; Saha BK
Front Nutr; 2020; 7():27. PubMed ID: 32309286
[TBL] [Abstract][Full Text] [Related]
33. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients.
Riquelme AJ; Calvo MA; Guzmán AM; Depix MS; García P; Pérez C; Arrese M; Labarca JA
J Clin Gastroenterol; 2003 Jan; 36(1):41-3. PubMed ID: 12488707
[TBL] [Abstract][
